Stronger Warnings Urged for Tamiflu

Manufacturer Roche Laboratories, Inc. should update Tamiflu labeling to include stronger warnings regarding the risk of psychiatric problems in users of the flu medicine, according to a U.S. Food and Drug Administration (FDA) committee. The FDA Pediatric Advisory Committee made its recommendations after evaluating reports of adverse events associated with use of the prescription influenza medication -- including delusions, confusion, and self-injury -- especially in children. The New York Times reports that "nearly 600 cases of psychiatric problems in Tamiflu patients have been reported, with 75 percent of them from Japan."

• FDA Information Page: Tamiflu
• NY Times: Panel Seeks New Warning on Flu Drug
• Tamiflu Side Effects and Safety (Roche Laboratories, Inc.)
• Tamiflu Information and Resources (FindLaw)